当前用于治疗套细胞淋巴瘤的一线疗法的临床试验。
Current trials for frontline therapy of mantle cell lymphoma.
机构信息
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
出版信息
J Hematol Oncol. 2018 Jan 27;11(1):13. doi: 10.1186/s13045-018-0556-x.
Abstract
Mantle cell lymphoma (MCL) is a rare and incurable subtype of non-Hodgkin's lymphoma that generally affects older individuals. However, the use of high-dose therapy and autologous stem cell transplant has improved significantly the prognosis of this hematological malignancy, but at the cost of increased toxicities, such as acute toxic death and secondary malignancies. But thanks to a rising understanding of the biology of MCL, the explosion of specifically targeted new efficacious agents, immunotherapy agents, and cellular therapies in the frontline setting, the prognosis of MCL is expected to improve dramatically.The initial treatment of MCL is currently not standardized and the therapeutic landscape of MCL is rapidly evolving. This review provides an extensive overview of the current frontline therapy trials for MCL and presents the results of innovative regimen, including some integrating novel agents and desintensified chemotherapy.
摘要
套细胞淋巴瘤（MCL）是一种罕见且无法治愈的非霍奇金淋巴瘤亚型，通常影响老年人。然而，高剂量化疗和自体干细胞移植的应用已经显著改善了这种血液恶性肿瘤的预后，但代价是增加了毒性，如急性毒性死亡和继发性恶性肿瘤。但是，由于对 MCL 生物学的认识不断提高，新型靶向有效药物、免疫治疗药物和细胞治疗药物在一线治疗中的应用不断增加，预计 MCL 的预后将显著改善。目前，MCL 的初始治疗尚未标准化，MCL 的治疗领域正在迅速发展。本综述广泛概述了目前 MCL 的一线治疗试验，并介绍了创新方案的结果，包括一些整合新型药物和减量化疗的方案。
相似文献
1
Current trials for frontline therapy of mantle cell lymphoma.当前用于治疗套细胞淋巴瘤的一线疗法的临床试验。
J Hematol Oncol. 2018 Jan 27;11(1):13. doi: 10.1186/s13045-018-0556-x.
2
High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.新型药物时代的高危套细胞淋巴瘤。
Curr Hematol Malig Rep. 2021 Feb;16(1):8-18. doi: 10.1007/s11899-021-00605-9. Epub 2021 Jan 28.
3
Emerging therapies in mantle cell lymphoma.套细胞淋巴瘤的新兴治疗方法。
J Hematol Oncol. 2020 Jun 17;13(1):79. doi: 10.1186/s13045-020-00914-1.
4
Mantle cell lymphoma: insights into therapeutic targets at the preclinical level.套细胞淋巴瘤：临床前水平治疗靶点的研究进展。
Expert Opin Ther Targets. 2020 Oct;24(10):1029-1045. doi: 10.1080/14728222.2020.1813718. Epub 2020 Aug 31.
5
Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies.套细胞淋巴瘤的新型疗法：通向无化疗策略之路
Oncology (Williston Park). 2013 Oct;27 Suppl 2:8-12.
6
Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop.套细胞淋巴瘤研究的最新进展与未来方向：2016年套细胞淋巴瘤联盟研讨会报告
Leuk Lymphoma. 2017 Jul;58(7):1561-1569. doi: 10.1080/10428194.2017.1283036. Epub 2017 Jan 31.
7
Non-chemotherapy Options for Newly Diagnosed Mantle Cell Lymphoma.新诊断的套细胞淋巴瘤的非化疗选择。
Curr Treat Options Oncol. 2021 Sep 15;22(11):98. doi: 10.1007/s11864-021-00900-w.
8
Mantle cell lymphoma: evolving management strategies.套细胞淋巴瘤：不断发展的治疗策略。
Blood. 2015 Jan 1;125(1):48-55. doi: 10.1182/blood-2014-05-521898. Epub 2014 Dec 11.
9
Mantle cell lymphoma: are current therapies changing the course of disease?套细胞淋巴瘤：当前的治疗方法是否正在改变疾病进程？
Curr Oncol Rep. 2009 Sep;11(5):371-7. doi: 10.1007/s11912-009-0050-2.
10
Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.套细胞淋巴瘤：风险适应性治疗及复发疾病治疗的作用
Curr Oncol Rep. 2022 Oct;24(10):1313-1326. doi: 10.1007/s11912-022-01297-x. Epub 2022 May 31.
引用本文的文献
1
Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations.利用 PRMT5 作为频繁 ATM 和 TP53 突变的套细胞淋巴瘤联合治疗的靶点。
Blood Cancer J. 2023 Feb 17;13(1):27. doi: 10.1038/s41408-023-00799-6.
2
3-Methyladenine but not antioxidants to overcome BACH2-mediated bortezomib resistance in mantle cell lymphoma.3-甲基腺嘌呤而非抗氧化剂可克服套细胞淋巴瘤中BACH2介导的硼替佐米耐药性。
Cancer Cell Int. 2021 May 26;21(1):279. doi: 10.1186/s12935-021-01980-2.
3
BAFF receptor antibody for mantle cell lymphoma therapy.治疗套细胞淋巴瘤的 BAFF 受体抗体。
Oncoimmunology. 2021 Mar 5;10(1):1893501. doi: 10.1080/2162402X.2021.1893501.
4
Drug resistance and Cancer stem cells.耐药性和癌症干细胞。
Cell Commun Signal. 2021 Feb 15;19(1):19. doi: 10.1186/s12964-020-00627-5.
5
Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States.美国商业保险患者套细胞淋巴瘤的治疗模式、不良事件、医疗资源利用和费用。
Cancer Med. 2019 Dec;8(17):7174-7185. doi: 10.1002/cam4.2559. Epub 2019 Oct 8.
6
Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma.抗体药物偶联物在淋巴恶性肿瘤和多发性骨髓瘤临床试验中的应用。
J Hematol Oncol. 2019 Sep 10;12(1):94. doi: 10.1186/s13045-019-0786-6.
7
Cyclin D1 + large B-cell lymphoma with altered CCND1 and BCL-6 rearrangements: a diagnostic challenge.伴有CCND1改变和BCL-6重排的细胞周期蛋白D1阳性大B细胞淋巴瘤：诊断挑战
Biomark Res. 2019 Jun 3;7:11. doi: 10.1186/s40364-019-0162-2. eCollection 2019.
8
Gastrointestinal Perforation after Rituximab Therapy in Mantle Cell Lymphoma: A Case Report.利妥昔单抗治疗套细胞淋巴瘤后发生胃肠道穿孔：一例报告
Case Rep Oncol. 2018 Nov 29;11(3):784-790. doi: 10.1159/000494828. eCollection 2018 Sep-Dec.
9
Identification of MMP9 as a novel key gene in mantle cell lymphoma based on bioinformatic analysis and design of cyclic peptides as MMP9 inhibitors based on molecular docking.基于生物信息学分析鉴定 MMP9 为套细胞淋巴瘤的新型关键基因，并基于分子对接设计环状肽 MMP9 抑制剂。
Oncol Rep. 2018 Nov;40(5):2515-2524. doi: 10.3892/or.2018.6682. Epub 2018 Sep 5.
本文引用的文献
1
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.阿卡替尼治疗复发或难治性套细胞淋巴瘤（ACE-LY-004）：一项单臂、多中心、2 期临床试验。
Lancet. 2018 Feb 17;391(10121):659-667. doi: 10.1016/S0140-6736(17)33108-2. Epub 2017 Dec 11.
2
Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network.在欧洲套细胞淋巴瘤网络的试验中，TP53 的表达与 MIPI 和 Ki-67 无关，与 MCL 的预后相关。
Blood. 2018 Jan 25;131(4):417-420. doi: 10.1182/blood-2017-07-797019. Epub 2017 Dec 1.
3
VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.VcR-CVAD诱导化疗序贯利妥昔单抗维持治疗可使套细胞淋巴瘤获得持久缓解：威斯康星肿瘤网络研究
Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e61-e67. doi: 10.1016/j.clml.2017.10.006. Epub 2017 Nov 4.
4
Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights.嵌合抗原受体T细胞疗法相关的细胞因子释放综合征：临床病理见解
Blood. 2017 Dec 7;130(23):2569-2572. doi: 10.1182/blood-2017-08-802413. Epub 2017 Oct 26.
5
Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.硼替佐米、克拉屈滨和利妥昔单抗用于晚期、新诊断及复发/难治性套细胞淋巴瘤和惰性淋巴瘤的2期开放标签研究。
Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):58-64. doi: 10.1016/j.clml.2017.09.001. Epub 2017 Sep 19.
6
CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course.CD200 表达在套细胞淋巴瘤中鉴定出一个独特的亚组患者，这些患者具有频繁的 IGHV 突变、SOX11 表达缺失和惰性临床病程。
Mod Pathol. 2018 Feb;31(2):327-336. doi: 10.1038/modpathol.2017.135. Epub 2017 Oct 6.
7
The potential for chemotherapy-free strategies in mantle cell lymphoma.套细胞淋巴瘤无化疗策略的潜力。
Blood. 2017 Oct 26;130(17):1881-1888. doi: 10.1182/blood-2017-05-737510. Epub 2017 Sep 12.
8
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.新诊断及复发的套细胞淋巴瘤：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2017 Jul 1;28(suppl_4):iv62-iv71. doi: 10.1093/annonc/mdx223.
9
mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.突变可识别出年轻的套细胞淋巴瘤患者，他们不能从强化化疗免疫治疗中获益。
Blood. 2017 Oct 26;130(17):1903-1910. doi: 10.1182/blood-2017-04-779736. Epub 2017 Aug 17.
10
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.抗CD19嵌合抗原受体T细胞引起的淋巴瘤缓解与高血清白细胞介素-15水平相关。
J Clin Oncol. 2017 Jun 1;35(16):1803-1813. doi: 10.1200/JCO.2016.71.3024. Epub 2017 Mar 14.
Zotero 插件